NCT05385809View on ClinicalTrials.gov

A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer

UnknownOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

July 30, 2022

Study Completion Date

December 31, 2023

Conditions
Unresectable Gastric Cancer
Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

Sponsors

Collaborators (1)

Innovent Biologics, Inc.
All Listed Sponsors
collaborator

Innovent Biologics, Inc.

OTHER

lead

Zhejiang Cancer Hospital

OTHER

NCT05385809 - A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer | Biotech Hunter | Biotech Hunter